Melanocortin receptor agonist
Melanotan I
Melanotan I after one dose: 50% at ~30 min, 25% at 60 min, 12.5% at 90 min.
Drawn from the half-life in the app's model, ~30 min. The model's figures
- Compound
- Melanotan I
- Symbol
- MT1
- Family
- Cosmetic and copper peptides
- Parts
- 14
- References
- 23
- Checked
- Last reviewed . Sources are listed below.
Overview
Melanotan I (MT-I) is the name Dorr and colleagues used in 2000 for [Nle4-D-Phe7]-alpha-MSH, a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH).1 Harms and colleagues, in a 2009 study of erythropoietic protoporphyria (EPP), name the same sequence, Nle4-D-Phe7-alpha-MSH, afamelanotide.3 Hadley and Dorr describe melanotan I as a linear peptide and melanotan II as a cyclic truncated peptide.4
The US prescribing information for Scenesse (afamelanotide) describes a synthetic peptide containing 13 amino acids, supplied as an implant of 16 mg.2 It gives Initial U.S. Approval as 2019 and the indication "to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)".2
The Australian Therapeutic Goods Administration (TGA) writes that "Melanotans are synthetic peptides that increase melanin production in the skin to give it a tanned appearance" and that they are "often listed on the label as Melanotan I or Melanotan II".6
The app's evidence badge is the app's own grade; the sources describe volunteer trials of 3 to 77 people, two phase 3 trials in 168 adults and cohorts.
How it works
Sources in this part
The Scenesse label states that afamelanotide "is a melanocortin receptor agonist and binds predominantly to MC1-R" and "increases production of eumelanin in the skin independently of exposure to sunlight or artificial UV light sources".2
In 7 volunteers given 0.16 mg/kg/day subcutaneously on weekdays for two weeks, Dorr and colleagues measured eumelanin as pyrrole-2,3,5-tricarboxylic acid (PTCA) in skin biopsies one week after the last dose.1 Forearm PTCA rose by a mean of 98% (P = 0.003) and forehead PTCA, measured in 3 volunteers, by 49% (P = 0.019).1 Forearm pheomelanin "did not significantly change from baseline", and the eumelanin to pheomelanin ratio went from 51:1 to 86:1 (P = 0.054).1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~30 min
- Bioavailability
- 75%
- Typical dose
- 0.5–1.5 mg/day
- Route
- SubQ
- Time to peak
- ~30 min
Sources in this part
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 30 minutes | In 3 men given melanotan I subcutaneously, Ugwu and colleagues report plasma half-lives "from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the beta-phase", and the Scenesse label gives an apparent half-life of "approximately 15 hr" for the implant.10,2 |
| Bioavailability | 75% by subcutaneous injection | In the same 3 men "the SC dose is completely bioavailable compared to the IV dose" and "No detectable drug levels were observed following PO dosing".10 |
| Time to peak | About 30 minutes | In the Ugwu text read, no time to peak after injection is given; for the 16 mg implant in 12 healthy adults the label gives a median Tmax of 36 hr and a mean maximum concentration of 3.7 ± 1.3 ng/mL.2 |
| Duration of activity | About 3 hours | Ugwu and colleagues report that tanning "peaked at 1 week following drug administration but was still present 3 weeks after completing the ten-dose regimen", and Levine and colleagues that "Peak changes were seen 1 to 3 weeks after therapy was completed".10,8 |
The chart uses the app's half-life, time to peak and mg dose with one schedule a trial reports, weekday injections for two weeks. Of the half-life figures above, only the beta phase (0.8 to 1.7 h) and the implant figure (about 15 hr) are longer than the app's; the absorption phase (0.07 to 0.79 h) spans 0.5 h.1,10,2
Level over 3 days
Level, as a share of the peak after one 1 mg dose
As studied: weekdays for two weeks1.
An illustration from a pharmacokinetic model using a half-life of 0.5 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Levine and colleagues, JAMA, 19918 | Randomized, placebo-controlled, double-blind8 | 28 healthy white men, skin types I to IV8 | 10 subcutaneous injections of NDP-alpha-MSH or saline over 12 days with sunscreen, 7 weeks of follow-up; dose not given in the source text8 | Skin darkening in skin types I or II (P less than .001) and III or IV (P much less than .001); none with placebo; peak 1 to 3 weeks after therapy ended8 |
| Ugwu and colleagues, Biopharm Drug Dispos, 199710 | Randomized crossover pharmacokinetic trial10 | 3 male volunteers10 | 0.16 mg/kg intravenously and orally, 0.08 to 0.21 mg/kg subcutaneously, ten doses over 2 weeks10 | Subcutaneous dose completely bioavailable against intravenous; no detectable levels after oral dosing; "Side-effects were minimal, consisting of occasional gastrointestinal upset and facial flushing"10 |
| Barnetson and colleagues, J Invest Dermatol, 200611 | Randomized, placebo comparator11 | 65 fair-skinned volunteers who completed the trial11 | 0.16 mg/kg subcutaneously into the abdomen, three 10-day cycles over 3 months11 | Melanin density up 41% (2.55 to 3.59) in the low minimal erythemal dose group and 12% (4.18 to 4.70) in the high group, both P < 0.0001 versus placebo; after treatment, sunburn cells reduced by more than 50% in volunteers with low baseline minimal erythemal dose and thymine dimers by 59% (P = 0.002), comparator not stated for these two11 |
| Fitzgerald and colleagues, Peptides, 200612 | Randomized, placebo comparison12 | 77 Caucasian individuals, with and without MC1R variant alleles12 | Dose and length not given in the source text | Melanin density rose versus placebo (p<0.001), and more in carriers of the variant alleles Val60Leu, Asp84Glu, Val92Met, Arg142His, Arg151Cys and Arg160Trp than in individuals with no variant alleles12 |
| Dorr and colleagues, Arch Dermatol, 20049 | Three open-label phase 1 studies with UV-B or sunlight: 4 melanotan I against 4 saline; 12 given melanotan I with UV-B; 8 randomized to sunlight alone or sunlight plus melanotan I9 | 8, 12 and 8 people in the three studies9 | 0.08 mg/kg/day for 10 days; 0.16 mg/kg/day for 10 days; 0.16 mg/kg 5 days a week for 4 weeks9 | Tanning in 3 of 4 given melanotan I in the first study, with 47% fewer sunburn cells at the irradiated neck site (comparator not stated in the source text); "Toxic effects due to MT-1 were minor, consisting of nausea and transient facial flushing"9 |
| Langendonk and colleagues, N Engl J Med, 201513 | Two multicenter, randomized, double-blind, placebo-controlled phase 3 trials13 | 168 adults with EPP enrolled: 74 in the European Union, 94 in the United States13 | 16 mg implant or placebo implant every 60 days: 9 months in the EU trial, 6 months in the US trial13 | Median pain-free time in direct sunlight: US 69.4 vs 40.8 hours (P = 0.04), EU 6.0 vs 0.8 hours (P = 0.005); phototoxic reactions EU 77 vs 146 (P = 0.04), US 46 vs 43 (P = 0.60)13 |
| Lim and colleagues, JAMA Dermatol, 201514 | Randomized, open-label (registry masking: none), proof-of-concept phase 1: afamelanotide plus narrowband UV-B versus narrowband UV-B alone14,16 | 55 adults with nonsegmental vitiligo over 15% to 50% of body surface area (the registry entry lists 56 enrolled)14,16 | 16 mg implant monthly for 4 months, with narrowband UV-B continued14 | Repigmentation at day 168 of 48.64% (95% CI, 39.49%-57.80%) versus 33.26% (95% CI, 24.18%-42.33%); no significant difference in phototype III; erythema in both groups, minor infections and nausea in the combination group14 |
Sources in this part
Sponsors and funders, where the sources state them: Clinuvel Pharmaceuticals sponsored the two EPP trials and is lead sponsor of the vitiligo trial in its registry entry, and funded the 2026 study by Griffin and colleagues together with a UK National Institute for Health and Care Research center.13,16,15 PubMed lists US National Cancer Institute grants for Ugwu (1997), Dorr (2000) and Dorr (2004), and a National Institute of Diabetes and Digestive and Kidney Diseases grant for Dorr (2000); the Levine (1991) record is typed "Research Support, Non-U.S. Gov't", and the Barnetson (2006) and Fitzgerald (2006) records show no funding.
Deeper analysis: the two phase 3 trials in erythropoietic protoporphyria
Langendonk and colleagues, writing in the New England Journal of Medicine in 2015, report two multicenter, randomized, double-blind, placebo-controlled trials, one at eight European porphyria centers and one at seven US centers.13 Patients were at least 18 years old with biochemically confirmed EPP and without clinically significant hepatic or other organ dysfunction, skin cancer, premalignant lesions or other photodermatoses; 86 received afamelanotide implants and 81 placebo.13 The primary end point was direct sunlight exposure without pain, between 10 a.m. and 3 p.m. in the EU trial or 10 a.m. and 6 p.m. in the US trial.13
Pain-free time in direct sunlight was longer with afamelanotide in both trials (US median 69.4 vs 40.8 hours, P = 0.04; EU 6.0 vs 0.8 hours, P = 0.005), but phototoxic reactions were fewer only in the EU trial (77 vs 146, P = 0.04), not the US trial (46 vs 43, P = 0.60).13 The Dermatology Life Quality Index "did not change over time in either study-drug group", while the disease-specific EPP-QOL questionnaire favored afamelanotide in both trials during treatment: in the EU trial the mean scores were 78.8 against 63.6 at day 120 (P = 0.005) and 79.7 against 67.2 at day 270 (P = 0.06; at day 60, P = 0.09), and in the US trial the mean change from baseline was 44.0 against 23.4 at day 60 (P < 0.001), 49.8 against 30.4 at day 120 (P < 0.001) and 51.1 against 36.8 at day 180 (P = 0.02); scores at day 360, 240 days after the last dose, were 38.4 against 45.4 (no P value given).13 There were no deaths; four serious adverse events occurred in the afamelanotide groups (subcapital humerus fracture, herniated disk, abdominal pain and benign compound nevus) and two in the placebo groups (pulmonary embolus and melanoma), all judged unrelated to the study drug by the principal investigator.13 Adverse events were "generally mild to moderate in severity", with "mild hyperpigmentation at the implant site in one third of the patients who received afamelanotide and moles that darkened in a few patients who received this drug".13
The study "was designed and sponsored by Clinuvel Pharmaceuticals", which supplied the medication and monitored the trial and was responsible for the accuracy and completeness of the recorded data; two US National Institutes of Health grants are also listed.13 The disclosures list consulting fees from Clinuvel to Dr. Bonkovsky, Dr. Rhodes and Dr. Goding, grants and personal fees to Dr. Edwards, grant support to Dr. Hamzavi and Dr. Lebwohl, and travel support to Dr. Neumann.13 The authors' limitations include that "the increased skin pigmentation in participants who received afamelanotide partially unblinded the trial" and that patients without increased pigmentation "continued to avoid sun exposure".13
The label and the EMA summary appear to report the US study with differently defined or averaged outcomes, so their figures are not directly comparable with 69.4 vs 40.8 hours: the label's Study CUV039 (93 subjects) gave a median of 64.1 hours for Scenesse against 40.5 for vehicle over 180 days in direct sunlight between 10 am and 6 pm on days with no pain, and the EMA summary describes 93 patients who "spent on average 116 hours in direct sunlight without experiencing pain" against 61 hours on placebo over a six-month period. The label also lists a 74-subject EU study (Study CUV029). The EMA committee decided that Scenesse's benefits are greater than its risks: "Although the additional time spent in sunlight was small, the Committee considered the possible improvements in quality of life, the unmet medical need in patients with EPP"; it authorised Scenesse under exceptional circumstances because "it has not been possible to obtain complete information about the benefits of Scenesse, in part due to the rarity of the disease".2,5
Deeper analysis: the pharmacokinetic study in 3 men
Ugwu and colleagues, writing in Biopharmaceutics and Drug Disposition in 1997, gave melanotan I to three male volunteers by three routes in a randomized crossover design.10 Clearance ranged from 0.12 to 0.19 L kg-1 h-1 and "3.9% or less of the dose was recovered in the urine"; the authors conclude "that SC administration is an efficacious method of delivering melanotan-I".10
Cohorts after authorisation
Biolcati and colleagues, in a longitudinal observational study of 115 patients with EPP who received 1023 implants over up to 8 years, report quality-of-life scores of 31 ± 24% of maximum before treatment and 74% after starting, and the authors report "Only minor adverse events attributable to afamelanotide, predominantly nausea".17 The single-center Erasmus MC cohort of Wensink and colleagues (117 patients, median follow-up 2.0 years), whose authors describe the results as associations, reports 6.1 more hours per week outside (95% CI, 3.62-8.67), a quality-of-life gain of 14.01%, and "no significant difference in number or duration of reactions"; three authors report Clinuvel payments, two for registry data entry and one grants and travel fees.18 The German postauthorisation study by Homey and colleagues (200 patients) states "This study was funded by CLINUVEL" and lists Clinuvel employees and stockholders among its authors.19 It reports serious treatment-emergent adverse events in 18.0% of patients (n = 36), 4 patients (2.0%) with a serious event assessed as related to afamelanotide, and, among 30.5% with pigmentary events, "No pigmentary lesions or expressions of concern were identified". The authors name as limitations a registry set up at each center at different times, a noninterventional design and, because all patients but one chose treatment, "no control data from patients without treatment".19
Doses reported in studies and on labels
Sources in this part
| Source | People | Dose and schedule reported |
|---|---|---|
| The app | Not a study | 0.5 to 1.5 mg/day is the app's typical dose range; none of the texts read reports a dose in mg per day for melanotan I. |
| Dorr and colleagues, 2000 and 20041 | Volunteers9 | 0.16 mg/kg/day subcutaneously, Monday to Friday, for two weeks (2000); 0.08 and 0.16 mg/kg/day for 10 days, and 0.16 mg/kg 5 days a week for 4 weeks (2004)1,9 |
| Scenesse label (US)2 | Adults with a history of phototoxic reactions from EPP2 | One 16 mg implant every 2 months, administered by a health care professional2 |
| EMA summary (EU)5 | Adult patients with EPP5 | One implant every 2 months; "Three implants per year are recommended; the maximum number is 4"5 |
Side effects reported
In the Scenesse label's table for adults with EPP given a 16 mg implant every 2 months (3 trials, 125 subjects on Scenesse and 119 on vehicle, through month 6), 12 reactions occurred in more than 2% of subjects: implant site reaction in 26 (21%) against 12 (10%), nausea in 24 (19%) against 17 (14%), skin hyperpigmentation in 5 (4%) against 0, and melanocytic nevus in 5 (4%) against 2 (2%), with oropharyngeal pain (7% against 5%), cough (6% against 3%), fatigue (6% against 3%), dizziness (4% against 3%) and respiratory tract infection (4% against 3%) among the others.2 Postmarketing reports include hypersensitivity (urticaria, angioedema and anaphylaxis).2 The label states that Scenesse "may lead to generalized increased skin pigmentation and darkening of pre-existing nevi and ephelides because of its pharmacologic effect" and that "A full body skin examination (twice yearly) is recommended".2
The EMA summary states "Scenesse must not be used in patients with reduced liver or kidney function", while the label states "The effect of renal or hepatic impairment on the pharmacokinetics of afamelanotide is unknown" and "There are no data on SCENESSE use in pregnant women".5,2
Arisi and colleagues examined 103 acquired melanocytic nevi in 15 adults with EPP given two implants 50 days apart, in a single group examined at baseline and at 5 and 12 months, and report reversible dermoscopic changes, "Dermoscopic changes suggestive of malignancy were never seen" and no new nevi.20
Habbema and colleagues' review of unregulated alpha-MSH analogues, commonly known as melanotan I and II, states that "increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi".21 They add that "Four case reports have described melanomas emerging from existing moles either during or shortly after the use of melanotan" and that "conclusive evidence linking these phenomena is lacking".21
The TGA lists headache, nausea, vomiting, loss of appetite and facial redness as the most common side effects of melanotan and "the risk of serious skin cancers" as the most concerning, and attributes reports of increased moles and freckles, kidney dysfunction and swelling of the brain to melanotan-II.6
Bloodwork and markers
Sources in this part
In the two phase 3 trials the authors write "There was no evidence that afamelanotide impeded bile flow or other hepatic functions" and that liver disease in EPP "is related to high protoporphyrin levels that do not change with afamelanotide treatment".13
Regulatory and anti-doping status
The EMA states that Scenesse was designated an orphan medicine on 8 May 2008 and withdrawn from the register of orphan medicines in December 2024 at the end of the 10-year period of market exclusivity, authorised on 22 December 2014 under exceptional circumstances, and "only prescribed by specialist doctors in recognised centres for treating EPP".5
The TGA states that "Melanotan is not approved for sale or use as a tanning agent in Australia", that it is illegal to supply tanning products containing melanotan without a doctor's prescription, and that these tanning agents "haven't been assessed for their quality or safety".6
FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, has a table headed "Bulk drug substances nominated but withdrawn" that names melanotan II; the page text, searched for "melanotan", returns that one row and no entry for melanotan I.22
The World Anti-Doping Agency's 2026 Prohibited List, in effect from 1 January 2026, covers in section S0 "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".23 A search of the list's text for "melan" returned no match, so it names neither melanotan nor afamelanotide.
Storage and handling
Sources in this part
For the 16 mg Scenesse implant, the label's storage line reads "Store in a refrigerator at 2°C – 8°C (36°F-46°F). Protect from light."2
What is not known
A search of PubMed on 16 November 2026 for afamelanotide in the title or summary text returned 104 records, and 23 of them also matched trial, randomized, randomised or phase. Among the texts read, the only human plasma half-life figures for injected melanotan I are the 3 men in the Ugwu report, and the label's apparent half-life of about 15 hours is for the implant in 12 healthy adults.10,2 None of the texts read gives a time to peak after an injection, and none reports a dose in mg per day.
The injection trials cited enrolled 3 to 77 people, with dosing periods from 10 days to 3 months where stated; Fitzgerald's dose and length are not given in the text read, and the 10 volunteers recruited by Griffin and colleagues (9 completed) were given a single 16 mg implant, not injections.10,12,9,11,15 A review by Minder and colleagues states "No late effects were reported in volunteers 25 years after the first exposure or after continuous long-term application of up to 8 years in EPP patients".7
Frequently asked questions
What is the half-life of melanotan I?
The app lists a half-life of about 30 minutes for melanotan I. Ugwu and colleagues reported plasma half-lives after subcutaneous dosing of 0.07 to 0.79 h (absorption phase) and 0.8 to 1.7 h (beta-phase) in 3 men, and the Scenesse label gives an apparent half-life of approximately 15 hours for the implant.10,2
Is melanotan I the same as afamelanotide?
Is melanotan I FDA approved?
The FDA label for Scenesse (afamelanotide), an implant given by a health care professional, gives Initial U.S. Approval as 2019, for adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.2 Habbema and colleagues call afamelanotide "the only α-MSH analogue that is approved for use in a limited number of medical indications", and the TGA states that "Melanotan is not approved for sale or use as a tanning agent in Australia".21,6
What is the bioavailability of melanotan I?
The app lists a bioavailability of 75% for melanotan I. Ugwu and colleagues reported that in 3 men "the SC dose is completely bioavailable compared to the IV dose" and that no drug was detectable after oral dosing.10
Does melanotan I need UV exposure to produce a tan?
The Scenesse label, for the implant in adults with EPP, states that afamelanotide "increases production of eumelanin in the skin independently of exposure to sunlight or artificial UV light sources".2 In Levine and colleagues' trial all 28 men used a high-potency sunscreen, those given the peptide darkened and "No darkening occurred in the subjects who were given a placebo", and Dorr and colleagues' open-label 2004 studies reported "significantly enhanced tanning of the back in the MT-1 group" with sunlight.8,9
Is melanotan I banned by WADA?
The World Anti-Doping Agency's 2026 Prohibited List text, searched for "melan", returned no match, so it names neither melanotan nor afamelanotide. Section S0 prohibits non-approved substances and S2 covers "other substances with similar chemical structure or similar biological effect(s)"; the search does not show whether either applies to melanotan I or afamelanotide.23
What side effects have been reported with melanotan I?
In the Scenesse label's table for adults with EPP given a 16 mg implant every 2 months, 12 reactions occurred in more than 2% of subjects, including implant site reaction in 21% and nausea in 19% on Scenesse against 10% and 14% on vehicle; skin hyperpigmentation occurred in 4% against 0% and melanocytic nevus in 4% against 2%; the other reactions in the table, such as oropharyngeal pain (7% against 5%) and cough (6% against 3%), were each more frequent on Scenesse.2
What do the sources report about melanotan and melanoma?
Habbema and colleagues state that "Four case reports have described melanomas emerging from existing moles either during or shortly after the use of melanotan" and that "conclusive evidence linking these phenomena is lacking".21 In the label's table, melanocytic nevus occurred in 4% on Scenesse against 2% on vehicle, and the label warns of "darkening of pre-existing nevi and ephelides" with a full body skin examination twice yearly.2 In the two phase 3 trials in EPP, moles darkened in a few patients given afamelanotide and a melanoma was a serious adverse event in the placebo groups.13 Arisi and colleagues report no new nevi in 15 adults with EPP given two implants.20
Guides, tools and comparisons
- Melanotan 1 dosageA guide that answers a question on this compound.
- Calculator for Melanotan IA calculator set up for this compound.
- Melanotan 1 vs melanotan 2A side-by-side with another compound.
- Previous in Cosmetic and copper peptides: Matrixyl Synthe'6The compound before this one in the class.
- Next in Cosmetic and copper peptides: Melanotan IIThe compound after this one in the class.
References
- Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol 2000. PMID 11045725
- SCENESSE (afamelanotide) implant, for subcutaneous use. US prescribing information. Clinuvel Inc. DailyMed, record published 13 May 2026. DailyMed label
- Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009. PMID 19656325
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006. PMID 16412534
- European Medicines Agency. Scenesse (afamelanotide): European public assessment report, summary page. EMA EPAR page
- Therapeutic Goods Administration (Australia). Don't risk using tanning products containing melanotan. TGA news. TGA news item
- Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet 2017. PMID 28063031
- Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA 1991. PMID 1658407
- Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol 2004. PMID 15262693
- Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos 1997. PMID 9113347
- Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006. PMID 16763547
- Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006. PMID 16293341
- Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med 2015. PMC4780255
- Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 2015. PMID 25230094
- Griffin LL, Kiss O, Halai P, et al. Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study. Photochem Photobiol Sci 2026. PMC13710583
- ClinicalTrials.gov. NCT01430195: Afamelanotide and narrow-band ultraviolet B (NB-UVB) light in the treatment of nonsegmental vitiligo (NSV). NCT01430195
- Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol 2015. PMID 25494545
- Wensink D, Wagenmakers MAEM, Barman-Aksozen J, et al. Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice. JAMA Dermatol 2020. PMC7081144
- Homey B, Schelonke K, Schlegel CM, et al. German cohort observational study to investigate the short- and long-term safety and clinical effectiveness of afamelanotide 16 mg (SCENESSE) in patients with erythropoietic protoporphyria (EPP). Photodermatol Photoimmunol Photomed 2025. PMC11906902
- Arisi M, Rossi M, Rovati C, et al. Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide. Photochem Photobiol Sci 2021. PMID 33721252
- Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol 2017. PMID 28266027
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA web page, content current as of 22 April 2026. FDA page
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In effect 1 January 2026. WADA 2026 list